Merck is discussing repurposing its COVID-19 antiviral, molnupiravir, to treat the rare Ebola Bundibugyo strain in the DRC outbreak.
Read More

Merck is discussing repurposing its COVID-19 antiviral, molnupiravir, to treat the rare Ebola Bundibugyo strain in the DRC outbreak.
Read More